Drug Trial Radar · NCT05963984
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Nov 16, 2023
Primary completion
Mar 20, 2025
Study completion Aug 28, 2025
Sponsor
- Lead sponsor
- Carrick Therapeutics LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Conditions
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Breast Cancer
Interventions
SamuraciclibDrug
Samuraciclib tablet by mouth once a day
FulvestrantDrug
Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Benefit Response (CBR)Time frame: From randomization until Week 24
Locations
32 sites in 5 countries. Site status is shown where the registry gives one.
Ocala Oncology Center PL DBA Florida Cancer Affiliates
Ocala, Florida
Mfsmc-Hjwci
Baltimore, Maryland
Saint Luke's Cancer Institute
Kansas City, Missouri
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania
The Center for Cancer and Blood Disorders
Fort Worth, Texas
Semmelweis Egyetem
Budapest, Hungary
Szent Borbala Korhaz
Tatabánya, Komárom-Esztergom, Hungary
Nograd Varmegyei Szent Lazar Korhaz
Salgótarján, Nógrád megye, Hungary
Cryptex Investigación Clínica S.A. de C.V.
Cuauhtémoc, Mexico
Oaxaca Site Management Organization S.C.
Oaxaca City, Mexico
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, Mexico
Actualidad Basada en la Investigación del Cáncer
Guadalajara, Jalisco, Mexico
Renati Innovation S.A.P.I de C.V
Guadalajara, Jalisco, Mexico
Soltmed SMO
Mexico City, Mexico City, Mexico
Hospital Infanta Cristina
Badajoz, Spain
Parc de Salut Mar - Hospital del Mar
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
MD Anderson Cancer Center
Madrid, Spain
Hospital Vithas Málaga
Málaga, Spain
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, Spain
Hospital Clinico de Valencia
Valencia, Spain
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria Comunidad de, Spain
Hospital Clinico San Carlos
Madrid, Madrid, Comunidad de, Spain
Gulhane Egitim ve Arastirma Hastanesi
Ankara, Turkey (Türkiye)
Gazi University
Ankara, Turkey (Türkiye)
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi
Ankara, Turkey (Türkiye)
Hacettepe Universite Hastaneleri
Ankara, Turkey (Türkiye)
Trakya University
Edirne, Turkey (Türkiye)
Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi
Istanbul, Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, Turkey (Türkiye)
I.E.U. Medical Point Hastanesi
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.